MOLECULAR STAGING OF LYMPH NODES--OUTCOME OF PROSTATE CA

Project Details

Description

DESCRIPTION: (adapted from the investigator's abstract) An estimated 50% of newly-diagnosed prostate cancer (PC) patients without pathologic evidence of pelvic lymph node (PLN) metastasis (NO) fail definitive local treatment. Although the risk of recurrence can be estimated from risk factors at presentation: size of the primary (cT stage), Gleason score and serum prostate specific antigen (sPSA) levels, direct evidence for PC metastasis in PLN has been lacking. Using a highly sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) assay to identify PC cells by PSA and prostate specific membrane antigen (PSM) gene messenger RNA (mRNA) expression, we found that 27 (82%) of 33 patients with localized PC and high risk features (T _ 2b or Gleason _7 or PSA _10 ng/ml), were RT-PCR positive while pathology identified PLN metastasis in only 4 (12%) (two sided P
StatusFinished
Effective start/end date7/1/996/30/02

Funding

  • National Cancer Institute
  • National Cancer Institute: $169,500.00

ASJC

  • Oncology
  • Cancer Research

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.